Bayer has recently regained momentum after a few difficult years. The agricultural business is benefiting from brisk demand and the pharmaceuticals division has been strengthened with new medicines. In addition, the glyphosate litigation in the US is no longer the dominant issue for investors. What’s going on at Bayer around the figures for the second quarter this Thursday (August 4), what analysts say and what the stock is doing.